These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 28758810)
1. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations. Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810 [TBL] [Abstract][Full Text] [Related]
2. Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations. Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Kurebayashi J J Med Econ; 2017 Nov; 20(11):1163-1169. PubMed ID: 28782387 [TBL] [Abstract][Full Text] [Related]
3. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma. Fornara P; Jocham D Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813 [TBL] [Abstract][Full Text] [Related]
4. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Sethi R; Sanfilippo N Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of depot leuprorelin. Periti P; Mazzei T; Mini E Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977 [TBL] [Abstract][Full Text] [Related]
6. Leuprorelin acetate in prostate cancer: a European update. Persad R Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449 [TBL] [Abstract][Full Text] [Related]
7. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan. Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824 [TBL] [Abstract][Full Text] [Related]
9. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Khan MS; O'Brien A Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419 [TBL] [Abstract][Full Text] [Related]
10. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. Merseburger AS; Björk T; Whitehouse J; Meani D J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079 [TBL] [Abstract][Full Text] [Related]
11. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984 [TBL] [Abstract][Full Text] [Related]
12. Leuprorelin acetate granulomas: case reports and review of the literature. Yasukawa K; Sawamura D; Sugawara H; Kato N Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Iannazzo S; Pradelli L; Carsi M; Perachino M Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489 [TBL] [Abstract][Full Text] [Related]
14. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Tunn UW; Wiedey K Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021 [TBL] [Abstract][Full Text] [Related]
15. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Crawford ED; Moul JW; Sartor O; Shore ND Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer. Ohlmann CH; Gross-Langenhoff M Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875 [TBL] [Abstract][Full Text] [Related]
17. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. Sharifi R; Browneller R; J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208 [TBL] [Abstract][Full Text] [Related]
18. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Berges R; Bello U Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425 [TBL] [Abstract][Full Text] [Related]
19. Randomised crossover trial to assess the tolerability of LHRH analogue administration. Williams G; Lindsay S; Bowsher WG Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381 [TBL] [Abstract][Full Text] [Related]
20. Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial. Lee SH; Lee HM; Kim SW; Lee ES; Hong SJ; Kim CS; Kang TW; Chung BH Yonsei Med J; 2014 Mar; 55(2):310-5. PubMed ID: 24532497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]